# ADVERSARIAL REVIEW -C-2009

## DeepSeek Attack
**Fatal Weakness 1: Lack of Patent-Eligible Subject Matter (35 U.S.C. § 101) – Abstract Idea Without Inventive Concept**

The claimed method is an abstract idea ineligible for patent protection. It merely recites the long-standing, fundamental human and business concepts of:
*   **Weighing the amount of background information (context) needed to make a responsible decision.**
*   **Recognizing that too little information leads to poor accountability, and too much leads to "analysis paralysis" or privacy issues.**
*   **Attempting to find a balance between these two extremes.**

The claims dress this abstract mental process in the metaphorical language of pharmacology ("dose," "therapeutic window," "toxicity," "potency"). However, the specification provides **no concrete, technical implementation** that transforms this abstract idea into a patent-eligible application. The "pharmacological data processing system" is a generic computing environment performing generic steps (quantify, calibrate, modulate) based on a metaphorical framework. There is no "inventive concept" that is significantly more than the abstract idea itself. The claims are directed to a result (regulated decision provenance) rather than a specific, non-conventional means of achieving it.

**Fatal Weakness 2: Indefiniteness (35 U.S.C. § 112(b)) – Key Terms Lack Objective Boundaries**

The claims and specification rely on core, self-coined metaphorical terms that have no established or objectively measurable meaning in the data processing arts, rendering the scope of the claims insolubly ambiguous.
*   **"Pharmacological mass of prior context":** This is a nonsensical analogy in this field. "Mass" is a physical property; "pharmacological" pertains to drugs. The specification fails to define how one would *quantify* this in a data system. What is the unit of measurement? Is it a count of data points, a computed weight, a semantic score? The claim provides no algorithm or standard.
*   **"Contextual potency relative to a therapeutic indication":** This is doubly indefinite. "Potency" is another pharmacological term with no data processing correlate. "Therapeutic indication of the decision event" is a vague, non-technical metaphor for the decision's purpose. There is no disclosed method for establishing a quantitative relationship between these two subjective concepts.
*   **"Decision toxicity":** This is a purely subjective, non-technical judgment (paralysis, latency, privacy compromise). The claim provides no objective metric or test for when "toxicity" occurs, making it impossible for a skilled artisan to determine the boundaries of the claimed invention or for the public to know what is infringed.

**Fatal Weakness 3: Lack of Enablement / Insufficient Disclosure (35 U.S.C. § 112(a)) – No Teaching of How to Make and Use the Invention**

The specification is purely conceptual and fails to enable a person skilled in the art to practice the invention without undue experimentation. It describes a desired *outcome* (regulating context within a "therapeutic window") but provides **zero technical details on *how* to achieve it**.
*   **How to Quantify?** The "Contextual Bioassay" requirement is stated but not implemented. What specific algorithms, data structures, or analysis techniques perform this "quantification"? The spec is silent.
*   **How to Calibrate?** The "Therapeutic Window Calibration" is described as "dynamic," but no feedback mechanism, learning algorithm, or calibration procedure is disclosed. How are the MED and MTD thresholds *actually determined* by the system? Are they user-input, learned from historical data, calculated via a specific formula? No guidance is given.
*   **How to Modulate?** "Modulating an administration rate of contextual history" is the final step. What are the *technical control

## Kimi Defense
None
